neratinib maleate - Profile

What are the generic drug sources for neratinib maleate and what is the scope of patent protection?

Neratinib maleate is the generic ingredient in one branded drug marketed by Puma Biotech and is included in one NDA. There are nine patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Neratinib maleate has two hundred and sixteen patent family members in thirty-six countries.

There is one tentative approval for this compound.

Summary for neratinib maleate

International Patents:	216
US Patents:	9
Tradenames:	1
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for neratinib maleate

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for neratinib maleate

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Generic filers with tentative approvals for NERATINIB MALEATE

Applicant	Application No.	Strength	Dosage Form
		40MG	TABLET;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Paragraph IV (Patent) Challenges for NERATINIB MALEATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
NERLYNX	Tablets	neratinib maleate	40 mg	208051	1	2021-07-19

US Patents and Regulatory Information for neratinib maleate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Puma Biotech	NERLYNX	neratinib maleate	TABLET;ORAL	208051-001	Jul 17, 2017		RX	Yes	Yes			Y
Puma Biotech	NERLYNX	neratinib maleate	TABLET;ORAL	208051-001	Jul 17, 2017		RX	Yes	Yes
Puma Biotech	NERLYNX	neratinib maleate	TABLET;ORAL	208051-001	Jul 17, 2017		RX	Yes	Yes			Y
Puma Biotech	NERLYNX	neratinib maleate	TABLET;ORAL	208051-001	Jul 17, 2017		RX	Yes	Yes
Puma Biotech	NERLYNX	neratinib maleate	TABLET;ORAL	208051-001	Jul 17, 2017		RX	Yes	Yes
Puma Biotech	NERLYNX	neratinib maleate	TABLET;ORAL	208051-001	Jul 17, 2017		RX	Yes	Yes
Puma Biotech	NERLYNX	neratinib maleate	TABLET;ORAL	208051-001	Jul 17, 2017		RX	Yes	Yes

Expired US Patents for neratinib maleate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Puma Biotech	NERLYNX	neratinib maleate	TABLET;ORAL	208051-001	Jul 17, 2017
Puma Biotech	NERLYNX	neratinib maleate	TABLET;ORAL	208051-001	Jul 17, 2017

International Patents for neratinib maleate

Country	Patent Number	Title	Estimated Expiration
Argentina	068932
Argentina	103866
Australia	2008312474
Brazil	122019023745
Brazil	PI0818464
Canada	2702930
Canada	2928071

Supplementary Protection Certificates for neratinib maleate

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
4066821	PA2025531	Lithuania		PRODUCT NAME: NERATINIBAS; REGISTRATION NO/DATE: EU/1/18/1311 20180831
3000467	2023C/527	Belgium		PRODUCT NAME: NERATINIB; AUTHORISATION NUMBER AND DATE: EU/1/18/1311 20180904
3000467	PA2023520	Lithuania		PRODUCT NAME: NERATINIBAS; REGISTRATION NO/DATE: EU/1/18/1311 20230526
4066821	122025000043	Germany		PRODUCT NAME: NERATINIB; REGISTRATION NO/DATE: EU/1/18/1311 20180831
4066821	CA 2025 00028	Denmark		PRODUCT NAME: NERATINIB; REG. NO/DATE: EU/1/18/1311 20180831
3000467	LUC00310	Luxembourg		PRODUCT NAME: NERATINIB; AUTHORISATION NUMBER AND DATE: EU/1/18/1311 20180904
3000467	26/2023	Austria		PRODUCT NAME: NERATINIB; REGISTRATION NO/DATE: EU/1/18/1311 (MITTEILUNG) 20180904

Investment Scenario, Market Dynamics, and Financial Trajectory for Neratinib Maleate

Last updated: February 3, 2026

Executive Summary

Neratinib maleate, marketed under the brand name Nerlynx, is an oral tyrosine kinase inhibitor (TKI) approved for the adjuvant treatment of early-stage HER2-positive breast cancer. It targets the HER2 receptor, crucial in aggressive breast cancers. Although patent protection and market exclusivity provide significant revenue streams temporarily, generic competition and evolving treatment paradigms influence long-term prospects. This analysis explores the current market landscape, development pipeline, competitive environment, and financial projections relevant to Neratinib maleate investors and stakeholders, emphasizing key factors driving growth, risks, and opportunities.

---

What Is the Current Market Landscape for Neratinib Maleate?

Regulatory Status and Market Approval

Approval Date	Region	Indication	Regulatory Body	Key Features
July 2017	US	Adjuvant treatment of early-stage HER2+ breast cancer	FDA	First-in-class irreversible TKI in this setting

Current Market Share and Sales Performance

Year	Global Revenue (USD millions)	Notes
2020	~$150M	Post-approval, initial adoption
2021	~$180M	Slight growth, expanding indications
2022	~$200M	Market stabilization, initial competition emerges

Sales Drivers

• Approved for early HER2-positive breast cancer post-trastuzumab
• Adherence to clinical guidelines (ASCO, NCCN) favoring Neratinib for high-risk patients
• Pharmacoeconomic considerations favoring oral therapy convenience over IV options

Market Penetration & Geographical Focus

Region	Market Share	Estimated Penetration	Key Market Drivers
North America	~70%	15-20% of eligible patients	Insurance coverage, clinical acceptance
European Union	~20%	10-15%	Reimbursement, clinical recommendations
Asia-Pacific	~10%	Emerging, ~5-10%	Growing breast cancer incidence, localized approval

---

Market Dynamics and Competitive Landscape

Key Competitors

Drug Name	Class	Approved Indications	Market Share	Comments
Lapatinib	Reversible TKI	HER2+ metastatic breast cancer	~45%	Competes in metastatic setting, less in adjuvant
Tucatinib	Irreversible TKI	HER2+ metastatic breast cancer	Growing (~15%)	Approved for metastatic, emerging in earlier lines
Pyrotinib	Irreversible TKI	HER2+ breast cancer (China)	Significant in China	Limited outside China, competition in metastatic settings
Neratinib	Irreversible TKI	HER2+ early-stage breast cancer (adjuvant)	Dominant in adjuvant	First-in-class with monopoly in adjuvant setting

Patent and Exclusivity Timeline

Patent Expiry	Details	Impact on Market
December 2023	Patent protection for neratinib claims	Potential generic entry
Data Exclusivity End	12 years from approval in US (~2029)	Data protection till then

Note: Patent expiry risks are mitigated by formulation patents, secondary patents, and regulatory data protections.

Market Opportunities

• Expanding indications: exploring neoadjuvant or metastatic settings
• Combination therapies: integrating neratinib with immunotherapy or chemo
• New formulations: extended-release or combination pills

Market Risks

• Genericization: imminent patent expiry could lead to price erosion
• Clinical competition: emerging TKIs with better efficacy or safety profiles
• Regulatory challenges: approvals for new indications or combination use

---

Financial Trajectory and Future Projections

Revenue Projections

Scenario	Year	Revenue Estimates (USD millions)	Key Assumptions
Conservative	2023	~$200M	Market saturation, patent expiry pending
Moderate Growth	2025	~$250-300M	Expanded indications, improved adherence
Aggressive	2027	~$350-400M	Combination therapies, pipeline success

Factors Affecting Revenue

• Patents and exclusivity status
• Market penetration in existing or new indications
• Pricing strategies and reimbursement policies
• Pipeline advancements and clinical trial outcomes

Cost Considerations

Cost Element	Description	Impact
R&D expenses	Clinical trials, pipeline development	Long-term innovation costs
Manufacturing & supply	Scale-up manufacturing, quality control	Cost efficiency strategies
Marketing & commercialization	Physician education, patient awareness campaigns	Growth enabling activities
Patent litigation & legal	Defense of IP rights	Potential cost variability

Financial Risks and Opportunities

Risk	Potential Impact	Mitigation Strategies
Patent expiry	Revenue erosion, generic competition	Portfolio diversification, lifecycle management
Market acceptance	Slow adoption in clinical practice	Education campaigns, guideline updates
Clinical trial failures	Delayed or failed expansion into new indications	Rigorous trial design, phased approaches

---

Comparison with Key Competitors

Aspect	Neratinib Maleate	Lapatinib	Tucatinib	Pyrotinib
Mechanism	Irreversible TKI	reversible TKI	Irreversible TKI	Irreversible TKI
Approved Indications	Adjuvant HER2+ breast cancer	Metastatic HER2+	Metastatic HER2+	Metastatic HER2+
First-in-Class Status	Yes	No	No	No
Patent Expiry (US)	December 2023 (planned)	Extended, no imminent	Extended, no imminent	Extended, no imminent
Market Penetration (2022)	High in adjuvant setting	High in metastatic	Growing in metastatic	Leading in China

---

Deep Dives: Key Topics to Monitor

Pipeline and Clinical Development

Candidate & Trial Phase	Indication	Expected Completion	Potential Impact
Neratinib combinations in metastatic settings	HER2+ metastatic breast cancer	2024-2026	Diversify revenue streams
New formulations (e.g., extended-release)	Adjuvant & metastatic	2025-2027	Improve adherence and convenience

Regulatory & Policy Developments

• FDA REMS and Risk Management: Impacts prescribing flexibility
• Pricing & Reimbursement Changes: Potential impact post-patent expiry
• Health Technology Assessments (HTAs): Influences adoption in various markets

Market Entry Barriers

Barrier	Description	Impact
Patent protections	Delay of generics unless litigation or patent cliff occurs	Temporary revenue shield
Clinical efficacy and safety data	Must demonstrate superiority or non-inferiority	Affects clinical guidelines and adoption
Pricing policies	Price controls may limit revenue potential	Especially relevant in Europe and emerging markets

---

Key Takeaways

• Market Positioning: Neratinib remains a first-in-class therapy within the adjuvant HER2+ breast cancer setting, with significant revenue from this niche pre-patent expiry.
• Patent Expiry Risks: Patent expiration in December 2023 threatens the entry of generics, likely to cause revenue decline unless mitigated by pipeline advancements.
• Pipeline and Expansion: Clinical trials exploring combination therapies and new formulations may hybridize growth projections over the next 3-5 years.
• Competitive Environment: While competitors such as tucatinib and lapatinib dominate other lines or metastatic settings, neratinib’s adjuvant niche provides unique positioning.
• Strategic Opportunities: Expanding indications, improving formulations, and leveraging clinical data could extend market durability.

---

Frequently Asked Questions (FAQs)

1. What is the primary therapeutic benefit of neratinib maleate?
   Neratinib maleate is a selective, irreversible TKI targeting HER2, approved for reducing recurrence risk in early HER2-positive breast cancer post-trastuzumab, improving disease-free survival.

2. When is patent expiration expected, and how does it impact the market?
   The key patent is scheduled to expire in December 2023, opening the market for generics and potentially reducing sales volume and price.

3. Are there significant pipeline developments that could influence long-term revenue?
   Yes. Ongoing trials are evaluating neratinib in metastatic settings, combination therapies, and new formulations, which could mitigate patent expiry impacts.

4. Who are the main competitors, and how does neratinib compare?
   Competitors include lapatinib and tucatinib. Neratinib’s unique niche is in adjuvant therapy due to its mechanism of action and approved indication.

5. What are the main risks associated with investing in neratinib maleate?
   Key risks include patent expiry, generic competition, evolving treatment standards, regulatory hurdles, and clinical trial outcomes affecting pipeline prospects.

---

References

[1] U.S. Food and Drug Administration (FDA). (2017). Nerlynx (neratinib) prescribing information.
[2] GlobalData Healthcare. (2022). HER2-positive breast cancer therapeutics market report.
[3] NCCN Clinical Practice Guidelines in Oncology. (2022). Breast Cancer, HER2-positive.
[4] FDA. (2022). Patent and exclusivity data for neratinib.
[5] EvaluatePharma. (2022). Pharmaceutical revenue forecasts.